Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Pharmosa Biopharm's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6875 vs VRTX, REGN, MRNA: Buyback Yield % Comparison
For the Biotechnology subindustry, Pharmosa Biopharm's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmosa Biopharm Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Pharmosa Biopharm's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmosa Biopharm (ROCO:6875) has a Buyback Yield % of -0.01 as of Sep. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pharmosa Biopharm and its competitors. According to the industry distribution chart, Pharmosa Biopharm ranks #83 out of 699 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Pharmosa Biopharm's Buyback Yield % too high?
Pharmosa Biopharm's current Buyback Yield % is -0.01. Based on the distribution chart, Pharmosa Biopharm ranks #83 out of 699 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmosa Biopharm has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmosa Biopharm ranks #83 out of 699 companies for Buyback Yield %. This places Pharmosa Biopharm in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pharmosa Biopharm and its competitors. Pharmosa Biopharm's current Buyback Yield % is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Pharmosa Biopharm (ROCO:6875) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$15.32, compared to a current price of NT$32.30 — trading 110.8% above its estimated fair value. The current Buyback Yield % is -0.01. Pharmosa Biopharm's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Buyback Yield % is -0.01 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmosa Biopharm (ROCO:6875) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmosa Biopharm stock appears to be overvalued.
The current stock price of NT$32.30 is trading 110.8% above its estimated GF Value™ of NT$15.32.
GuruFocus considers Pharmosa Biopharm to be Significantly Overvalued.
Key valuation signals for ROCO:6875:
Buyback Yield %: -0.01
GF Value™: NT$15.32 vs. price of NT$32.30 (110.8% above fair value)
No single metric tells the full story. See the ROCO:6875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
27GF Score
Get the complete analysis for ROCO:6875
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6875 has been successfully added to your 
